1
|
Islam MT, Zihad SMNK, Rahman MS, Sifat N, Khan MR, Uddin SJ, Rouf R. Agathisflavone: Botanical sources, therapeutic promises, and molecular docking study. IUBMB Life 2019; 71:1192-1200. [DOI: 10.1002/iub.2053] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Accepted: 04/04/2019] [Indexed: 12/14/2022]
Affiliation(s)
- Muhammad Torequl Islam
- Department for Management of Science and Technology DevelopmentTon Duc Thang University Ho Chi Minh City Vietnam
- Faculty of PharmacyTon Duc Thang University Ho Chi Minh City Vietnam
| | - S. M. Neamul Kabir Zihad
- Pharmacy Discipline, Life Science SchoolKhulna University Khulna Bangladesh
- Department of PharmacyAtish Dipankar University of Science & Technology Dhaka Bangladesh
| | - Md. Shamim Rahman
- Biotechnology & Genetic Engineering Discipline, Life Science SchoolKhulna University Khulna Bangladesh
| | - Nazifa Sifat
- Pharmacy Discipline, Life Science SchoolKhulna University Khulna Bangladesh
| | - Md. Roich Khan
- Department of Pharmacy, Life Science FacultyBangabandhu Sheikh Mujibur Rahman Science & Technology University Gopalganj Bangladesh
| | - Shaikh Jamal Uddin
- Pharmacy Discipline, Life Science SchoolKhulna University Khulna Bangladesh
| | - Razina Rouf
- Department of Pharmacy, Life Science FacultyBangabandhu Sheikh Mujibur Rahman Science & Technology University Gopalganj Bangladesh
| |
Collapse
|
3
|
Urpi-Sarda M, Almanza-Aguilera E, Llorach R, Vázquez-Fresno R, Estruch R, Corella D, Sorli JV, Carmona F, Sanchez-Pla A, Salas-Salvadó J, Andres-Lacueva C. Non-targeted metabolomic biomarkers and metabotypes of type 2 diabetes: A cross-sectional study of PREDIMED trial participants. DIABETES & METABOLISM 2018; 45:167-174. [PMID: 29555466 DOI: 10.1016/j.diabet.2018.02.006] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/20/2017] [Revised: 01/24/2018] [Accepted: 02/13/2018] [Indexed: 01/20/2023]
Abstract
AIM To characterize the urinary metabolomic fingerprint and multi-metabolite signature associated with type 2 diabetes (T2D), and to classify the population into metabotypes related to T2D. METHODS A metabolomics analysis using the 1H-NMR-based, non-targeted metabolomic approach was conducted to determine the urinary metabolomic fingerprint of T2D compared with non-T2D participants in the PREDIMED trial. The discriminant metabolite fingerprint was subjected to logistic regression analysis and ROC analyses to establish and to assess the multi-metabolite signature of T2D prevalence, respectively. Metabotypes associated with T2D were identified using the k-means algorithm. RESULTS A total of 33 metabolites were significantly different (P<0.05) between T2D and non-T2D participants. The multi-metabolite signature of T2D comprised high levels of methylsuccinate, alanine, dimethylglycine and guanidoacetate, and reduced levels of glutamine, methylguanidine, 3-hydroxymandelate and hippurate, and had a 96.4% AUC, which was higher than the metabolites on their own and glucose. Amino-acid and carbohydrate metabolism were the main metabolic alterations in T2D, and various metabotypes were identified in the studied population. Among T2D participants, those with a metabotype of higher levels of phenylalanine, phenylacetylglutamine, p-cresol and acetoacetate had significantly higher levels of plasma glucose. CONCLUSION The multi-metabolite signature of T2D highlights the altered metabolic fingerprint associated mainly with amino-acid, carbohydrate and microbiota metabolism. Metabotypes identified in this patient population could be related to higher risk of long-term cardiovascular events and therefore require further studies. Metabolomics is a useful tool for elucidating the metabolic complexity and interindividual variation in T2D towards the development of stratified precision nutrition and medicine. Trial registration at www.controlled-trials.com: ISRCTN35739639.
Collapse
Affiliation(s)
- M Urpi-Sarda
- Biomarkers and Nutrimetabolomic Laboratory, Department of Nutrition, Food Sciences and Gastronomy, XaRTA, INSA-UB, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain; CIBER de Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III, Barcelona, Spain.
| | - E Almanza-Aguilera
- Biomarkers and Nutrimetabolomic Laboratory, Department of Nutrition, Food Sciences and Gastronomy, XaRTA, INSA-UB, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain; CIBER de Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III, Barcelona, Spain
| | - R Llorach
- Biomarkers and Nutrimetabolomic Laboratory, Department of Nutrition, Food Sciences and Gastronomy, XaRTA, INSA-UB, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain; CIBER de Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III, Barcelona, Spain
| | - R Vázquez-Fresno
- Biomarkers and Nutrimetabolomic Laboratory, Department of Nutrition, Food Sciences and Gastronomy, XaRTA, INSA-UB, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain; Department of Computing Science and Biological Sciences, University of Alberta, Edmonton, Canada
| | - R Estruch
- Department of Internal Medicine, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain; CIBER Pathophysiology of Obesity and Nutrition (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain
| | - D Corella
- CIBER Pathophysiology of Obesity and Nutrition (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain; Department of Preventive Medicine and Public Health, University of Valencia, Valencia, Spain
| | - J V Sorli
- CIBER Pathophysiology of Obesity and Nutrition (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain; Department of Preventive Medicine and Public Health, University of Valencia, Valencia, Spain
| | - F Carmona
- Statistics Department, Biology Faculty, University of Barcelona, Barcelona, Spain
| | - A Sanchez-Pla
- Statistics Department, Biology Faculty, University of Barcelona, Barcelona, Spain
| | - J Salas-Salvadó
- CIBER Pathophysiology of Obesity and Nutrition (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain; Human Nutrition Unit, Biochemistry and Biotechnology Department. Hospital Universitari de Sant Joan de Reus, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Reus, Spain
| | - C Andres-Lacueva
- Biomarkers and Nutrimetabolomic Laboratory, Department of Nutrition, Food Sciences and Gastronomy, XaRTA, INSA-UB, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain; CIBER de Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III, Barcelona, Spain.
| |
Collapse
|